Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers

详细信息    查看全文

• 作者：Jaswinder Singh Sodhi (1)
  Nayeem Wani (3)
  Samoon Jeelani (2)
  Sajad Geelani (2)
  Fehmida Akhtar (3)
  Gul Javid (1)
  Gh Nabi Yattoo (1)
  Altaf Shah (1)
  Gh Mohd Gulzar (1)
  Mushtaq A. Khan (1)
  Shaheena Parveen (1)
  Riyaz-u Saif (1)
  Abid Showkat (1)
  
• 关键词：Adverse reaction ; Anti ; HBc ; Blood transfusion ; HBV DNA ; Nosocomial infection ; Occult HBV infection
• 刊名：Indian Journal of Gastroenterology
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：32
• 期：5
• 页码：291-296
• 全文大小：131KB
• 参考文献：1. Lee WM. Hepatitis B, virus infection. N Engl J Med. 1997;337:1733-5. CrossRef
  2. Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in hemato-oncological malignancies and liver injury following chemotherapy. Eur J Haematol. 2005;74:158-5. CrossRef
  3. Onozawa M, Hoshino S, Izumiyama K, et al. Progressive disappearance of acute hepatitis B surface antigen antibody and reverse seroconversion after allogenic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616-. CrossRef
  4. Hui CK, Cheung WWW, Zhong HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing chemotherapy. Gastroenterology. 2006;131:59-8. CrossRef
  5. Solden K, Davison K, Dow B. Estimates of the frequency of HBV, HCV and HIV infection donation entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill. 2005;10:17-.
  6. Lin CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol. 2006;36 Suppl 1:533-4.
  7. Gomes SA, Yoshida CF, Niel C. Detection of hepatitis B virus DNA in hepatitis B surface antigen-negative serum by polymerase chain reaction: evaluation of different primer pairs and condition. Acta Virol. 1996;40:133-.
  8. UNAIDS/WHO. AIDS epidemic update: December 2006. UNAIDS/06.29E. Geneva: UNAIDS, 2006
  9. Hughes VC, Wright PA. Donor screening and component preparation. In: Harmening DM (ed) Modern Blood Banking and Transfusion Practices. 5th ed. Philadelphia: Davis FA; 2008. p. 2010-3.
  10. Sawke NG, Sawke GK. Preventing post transfusion hepatitis by screening blood donors for IgM antibody to hepatitis B core antigen. J Glob Infect Dis. 2010;2:246-. CrossRef
  11. Patwari SI, Irshad M, Gandhi BM, Joshi YK, Nundy S, Tandon BN. Post transfusion hepatitis. A prospective study. Indian J Med Res. 1986;84:508-2.
  12. Sharaf-Eldeem S, Salama K, Eldermerdash S, Hassan HMS, Semesem M. Hepatitis B and C viruses in Egyptian children with malignancy. J Medical Sci. 2007;7:1003-. CrossRef
  13. Arora B, Joshi YK, Salhan RN, Arya S, Prakash S. Transfusion associated hepatitis in children with haematological malignancy in Northern India. Med Pediatr Oncol. 2003;41:166-. CrossRef
  14. Ayan RI, Yilmaz G, Gorgem O, Badur S. Sero-prevalence of hepatitis B, hepatitis C in children with hematological malignancy in Turkey. Med Pediatr Oncol. 2000;34:102-. CrossRef
  15. Cesaro SM, Petris G, Rosetti R, et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood. 1997;90:1315-0.
  16. Kim SM, Lee KS, Park CJ, et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect. 2007;54:185-1. CrossRef
  17. Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42:813-. CrossRef
  18. Tillman HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. J Hepatol. 2003;39:206-1. CrossRef
  19. Yeo W, Chan PKS, Zhong S, et al. Frequency of HBV reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299-07. CrossRef
  20. Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B reactivation after cessation of pre-emptive lamivudine in lymphoma patients treated with Rituximab plus CHOP. Ann Hematol. 2004;83:769-4. CrossRef
  21. Thoai Duong L, Annabelle Servant D, Sebastien B, et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assay in detection of HBsAg mutant forms. J Clin Microbiol. 2006;44:2321-. CrossRef
  22. Kant L, Arora NK. Transmission of hepatitis B in children, Indian scenario. In: Sarin SK, Singhal AK, (eds). Hepatitis B in India: Problems and Prevention. 1st ed. Delhi: CBS Publications; 1996. p. 21-2.
  23. Torbensen M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479-6. CrossRef
  24. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with hematological malignancies. Br J Haematol. 2007;136:699-2. CrossRef
  
• 作者单位：Jaswinder Singh Sodhi (1)
  Nayeem Wani (3)
  Samoon Jeelani (2)
  Sajad Geelani (2)
  Fehmida Akhtar (3)
  Gul Javid (1)
  Gh Nabi Yattoo (1)
  Altaf Shah (1)
  Gh Mohd Gulzar (1)
  Mushtaq A. Khan (1)
  Shaheena Parveen (1)
  Riyaz-u Saif (1)
  Abid Showkat (1)
  
  1. Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, 190 011, India
  3. Department of Blood Transfusion and Immunohematology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, 190 011, India
  2. Department of Clinical Hematology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, 190 011, India
  

文摘

Background Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased mortality. Multiple transfusions of blood and blood-related products are a potential source. Aims This study aims to assess the incidence of hepatitis B surface antigen (HBsAg) seroconversion in cancer patients receiving transfusion of blood or blood-related products and identify possible reasons for infection in these patients. Material and Methods Patients of cancer receiving blood products, who were HBsAg-, anti-hepatitis B core (HBc)-, and HBV DNA-negative prior to transfusion, were tested for HBsAg by ELISA at 6, 12, and 24?weeks after the last transfusion. Blood donors were screened for HBsAg by ELISA. Results Twenty of 3,600 (0.56?%) blood donors tested positive for HBsAg and were rejected. Nine of 150 (6?%) cancer patients became HBsAg-positive posttransfusion which included seven patients who presented with acute hepatitis B and other two patients who remained HBsAg-positive without hepatitis. In 6/9 (66.6?%) patients, HBsAg positivity was related to blood transfusion as their corresponding blood donors on retesting the stored samples were positive for anti-HBc antibody and HBV DNA. In other three patients, the cause of their HBsAg positivity could not be ascertained. Conclusion Occult HBV infection in blood donors is a potential source of posttransfusion HBV infection in recipients. Anti-HBc antibody and HBV DNA should be tested in blood donors especially when blood is given to cancer patients receiving chemotherapy.